FY25 consensus $2B. Raises FY25 adjusted EBITDA view to $118M-$121M from $105M-$110M. Guidance does not assume any impact from pending Evolent ACO business transaction. More than 80% of Adjusted EBITDA expected to convert to free cash flow in full-year 2025. Expects to end FY’25 with at least $410M in cash and equivalents pro forma for ACO transaction.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health reports Q3 adjusted EPS 29c, consensus 22c
- Privia Health Mourns Loss of Board Member
- Privia Health price target raised to $22 from $21 at Barclays
- Strategic Acquisition Boosts Privia Health’s Growth Potential with Evolent Health’s ACO Business
- Privia Health Group: Hold Rating Amid Growth Prospects and Integration Risks Post-Evolent Health Acquisition